Simply Wall St.
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib
📈
AI Sentiment
Highly Positive
9/10
- Home
- RLAY
as of 02-11-2026 4:00pm EST
$9.15
+$0.16
+1.78%
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.3B | IPO Year: | 2020 |
| Target Price: | $15.75 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.77 - $9.25 | Next Earning Date: | 02-24-2026 |
| Revenue: | $8,355,000 | Revenue Growth: | -16.50% |
| Revenue Growth (this year): | 19.96% | Revenue Growth (next year): | -32.66% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -248867000.0 | FCF Growth: | N/A |
AI-Powered RLAY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 76.58%
76.58%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
Bergstrom Donald A
Sell
President, R&D
RLAY Jan 28, 2026
Avg Cost/Share
$8.45
Shares
2,686
Total Value
$22,696.70
Owned After
420,047
SEC Form 4
Catinazzo Thomas
Sell
Chief Financial Officer
RLAY Jan 28, 2026
Avg Cost/Share
$8.45
Shares
1,695
Total Value
$14,322.75
Owned After
249,301
SEC Form 4
Rahmer Peter
Sell
See remarks
RLAY Jan 28, 2026
Avg Cost/Share
$8.45
Shares
1,354
Total Value
$11,441.30
Owned After
276,610
SEC Form 4
Bergstrom Donald A
Sell
President, R&D
RLAY Jan 27, 2026
Avg Cost/Share
$7.62
Shares
18,895
Total Value
$143,979.90
Owned After
420,047
SEC Form 4
Catinazzo Thomas
Sell
Chief Financial Officer
RLAY Jan 27, 2026
Avg Cost/Share
$7.62
Shares
13,820
Total Value
$105,308.40
Owned After
249,301
SEC Form 4
Rahmer Peter
Sell
See remarks
RLAY Jan 27, 2026
Avg Cost/Share
$7.62
Shares
11,684
Total Value
$89,032.08
Owned After
276,610
SEC Form 4
Patel Sanjiv
Sell
President and CEO
RLAY Jan 6, 2026
Avg Cost/Share
$7.82
Shares
43,168
Total Value
$337,573.76
Owned After
661,041
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | RLAY | President, R&D | Jan 28, 2026 | Sell | $8.45 | 2,686 | $22,696.70 | 420,047 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jan 28, 2026 | Sell | $8.45 | 1,695 | $14,322.75 | 249,301 | |
| Rahmer Peter | RLAY | See remarks | Jan 28, 2026 | Sell | $8.45 | 1,354 | $11,441.30 | 276,610 | |
| Bergstrom Donald A | RLAY | President, R&D | Jan 27, 2026 | Sell | $7.62 | 18,895 | $143,979.90 | 420,047 | |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jan 27, 2026 | Sell | $7.62 | 13,820 | $105,308.40 | 249,301 | |
| Rahmer Peter | RLAY | See remarks | Jan 27, 2026 | Sell | $7.62 | 11,684 | $89,032.08 | 276,610 | |
| Patel Sanjiv | RLAY | President and CEO | Jan 6, 2026 | Sell | $7.82 | 43,168 | $337,573.76 | 661,041 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
Motley Fool
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run
📊
AI Sentiment
Positive
6/10
Compare RLAY vs Leading Stocks
See how RLAY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.